Orgenesis Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORGS research report →
Companywww.orgenesis.com
Orgenesis Inc. , a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network.
- CEO
- Vered Caplan
- IPO
- 2012
- Employees
- 146
- HQ
- Germantown, MD, US
Price Chart
Valuation
- Market Cap
- $2.33M
- P/E
- -0.24
- P/S
- 4.39
- P/B
- -0.62
- EV/EBITDA
- -0.40
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -1080.19%
- Op Margin
- -10120.00%
- Net Margin
- -10445.47%
- ROE
- -1683.22%
- ROIC
- -3156.92%
Growth & Income
- Revenue
- $530.00K · -98.53%
- Net Income
- $-55,361,000 · -271.82%
- EPS
- $-1.91 · -223.73%
- Op Income
- $-53,636,000
- FCF YoY
- 54.65%
Performance & Tape
- 52W High
- $5.89
- 52W Low
- $0.02
- 50D MA
- $0.30
- 200D MA
- $0.84
- Beta
- 3.07
- Avg Volume
- 1.94K
Get TickerSpark's AI analysis on ORGS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 5, 25 | MALIK ARIEL | other | 0 |
| Dec 12, 24 | Adler Yaron | other | 1,750 |
| Dec 12, 24 | PELAVIN ADAM | other | 1,250 |
| Dec 12, 24 | PELAVIN ADAM | other | 625 |
| Dec 12, 24 | Nanda Ashish | other | 1,835 |
| Dec 12, 24 | NAGARAJ SANTHOSH | other | 1,250 |
| Dec 12, 24 | NAGARAJ SANTHOSH | other | 625 |
| Dec 12, 24 | Vider Itzhak | other | 1,500 |
| Dec 12, 24 | BHALAJI JAGANNATHAN | other | 1,250 |
| Dec 12, 24 | BHALAJI JAGANNATHAN | other | 625 |
Our ORGS Coverage
We haven't published any research on ORGS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ORGS Report →